|
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial |
|
|
|
Titel: |
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial |
Auteur: |
Yang, Yunpeng Zhou, Jianya Zhou, Jianying Feng, Jifeng Zhuang, Wu Chen, Jianhua Zhao, Jun Zhong, Wei Zhao, Yanqiu Zhang, Yiping Song, Yong Hu, Yi Yu, Zhuang Gong, Youling Chen, Yuan Ye, Feng Zhang, Shucai Cao, Lejie Fan, Yun Wu, Gang Guo, Yubiao Zhou, Chengzhi Ma, Kewei Fang, Jian Feng, Weineng Liu, Yunpeng Zheng, Zhendong Li, Gaofeng Wu, Ning Song, Wei Liu, Xiaoqing Zhao, Shijun Ding, Lieming Mao, Li Selvaggi, Giovanni Yuan, Xiaobin Fu, Yuanqing Wang, Tao Xiao, Shanshan Zhang, Li |
Verschenen in: |
Lancet respiratory medicine |
Paginering: |
Jaargang 8 () nr. 1 pagina's 45-53 |
Jaar: |
2020 |
Inhoud: |
|
Uitgever: |
Elsevier Ltd |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|